NCT06187285Completed
Efficay and Safety of Empagliflozin Versus Sitagliptin for the In-patient Management of Hyperglycemia
Efficay and Safety of Empagliflozin Versus Sitagliptin for the In-patient Management of Hyperglycemia: Randomised Control
Source: ClinicalTrials.gov · Last updated 13 Jun 2025
Brief summary (registry, in English)
Clinical guidelines from professional organizations have recommended the use of multidose insulin regimens as the preferred therapy for glycaemic control in patients admitted to hospital in a non-intensive-careunit setting. The use of a basal-bolus regimen with a once daily basal insulin and rapid-acting insulin analogs before meals has been shown to improve glycaemic control and to reduce the rate of hospital complications in general medical and surgical patients with type 2 diabetes.The basal-bolus regimen however is labour intensive, requiring several insulin injections, and is associated with a high risk of hypoglycaemia. Hypoglycaemia has been reported in 12% to 32% of patients in general medicine and surgery with type 2 diabetes treated with basal-bolus insulin regimens.Because of these limitations, alternative treatment regimens are needed that could improve glycaemic control and clinical outcomes, while facilitating care and minimising the risk of hypoglycaemia in patients with diabetes.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 220 (actual)
- First submitted
- 16 Dec 2023
- Start date
- 1 Jan 2024
- Primary completion date
- 1 May 2025
- Lead sponsor
- Medanta, The Medicity, India
- Diseases
- Type 2 diabetes
- NCT number
- NCT06187285
What you commit to
- Study type: Interventional
- Participants enrolled: 220
- From 1 Jan 2024 to the primary completion date, 1 May 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Type 1 diabetes,
- Hyperglycaemia without a known history of diabetes
- Pregnancy, and any mental health condition rendering the patient unable to give informed consent
Lab values
- Patients with a blood glucose concentration greater than 400mg/dL or with current or previous history of diabetic ketoacidosis,
- Clinically relevant hepatic disease or impaired renal function \[eGFR\] \<30 mL/min per 1•73 m²)
Other
- Patients expected to be without oral intake for more than 48 h
- Patients admitted to or expected to require admission to an intensive care unit
- Current or recurrent uti(more than 2 times in last 6 months)
Who the study is looking for
- Patients aged 18-years and above with type 2 diabetes and a random blood glucose concentration of 140-400 mg/dL who were being treated with diet or oral antidiabetic drugs or had a total daily insulin dose of 0•6 units per kg or less, admitted to general medicine or surgery
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Division Of Endocrinology & Diabetes, Medanta The Medicity Coordinator of this site? Confirm its status | Gurgaon | India | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.